Eli Lilly Weight-Loss Drug Could Also Treat Heart Failure, Study Shows

Key TakeawaysTirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro and obesity medication Zepbound, reduced the risk of heart failure outcomes by 38% versus placebo in a Phase 3 trial.Participants also saw a 15.7% reduction in body weight.Eli Lilly plans to submit the study results to the FDA later this year. The active ingredient in Eli Lilly's (LLY) flagship weight-loss drug has a new potential indication: heart failure treatment. Tirzepatide, sold as Mounjaro to treat Type 2 diabetes a ...